Mediar Therapeutics nominates candidates for lead fibrosis programs
Oct. 25, 2023
Mediar Therapeutics Inc. has announced the nomination of two first-in-class monoclonal antibody clinical candidates for fibrosis. The first, MTX-463, is designed to neutralize WISP-1 signaling. The second candidate, MTX-474, is designed to neutralize EphrinB2 signaling.